A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
Clinical trial NCT04315701 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04315701
- Sponsor
- University of Southern California
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-17
- Primary completion
- 2026-12-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.